Redcare Pharmacy NV delivers a robust second‑quarter performance amid accelerating digital pharmacy growth
Redcare Pharmacy NV, the Netherlands‑based online pharmacy that supplies prescription and non‑prescription medicines, pharmacy‑related beauty and personal‑care items, as well as natural food and health products, has announced a strong second‑quarter result that outpaces its own growth trajectory in the first half of the year.
Revenue and margin expansion
- Revenue: The company’s consolidated sales rose 20 % year‑on‑year to €853 million, compared with €709 million in the same period a year earlier.
- EBITDA: Adjusted EBITDA increased 63 % to €29.6 million, reflecting a significant tightening of operating leverage.
- Margin performance: The EBITDA margin reached a decade‑high, underscoring the firm’s ability to translate higher sales into improved profitability.
The growth was driven by a surge in both prescription and over‑the‑counter product sales, with the e‑prescription (e‑Rx) channel in Germany emerging as a key driver. In addition, international operations reported for the first time a profitable quarter, adding a new dimension to the company’s earnings profile.
Market reaction
Shares of Redcare Pharmacy NV have nearly doubled over recent months, reflecting investor confidence in the company’s expanding digital footprint. The market’s enthusiasm has been bolstered by the strong earnings call, where management reiterated guidance that anticipates continued momentum in e‑Rx penetration and international expansion.
Strategic context
- Digital transformation: Redcare’s investment in technology and logistics has positioned it as a leader in the European online pharmacy market.
- Product diversification: The company’s portfolio extends beyond pharmaceuticals to include natural health products, broadening revenue streams and reducing reliance on any single category.
- Geographical reach: While Germany remains the largest market, Redcare’s international presence continues to grow, now contributing to profitability for the first time.
Outlook
Management maintained its outlook for the remainder of 2026, noting that the company is well‑placed to capitalize on the ongoing shift toward digital prescription fulfillment. The firm’s cash position remains healthy, supporting continued investment in infrastructure and market expansion.
Key takeaways
| Metric | 2026 Q2 | YoY Change |
|---|---|---|
| Revenue | €853 million | +20 % |
| Adjusted EBITDA | €29.6 million | +63 % |
| EBITDA Margin | 10‑year high | — |
Redcare Pharmacy NV’s latest results illustrate how a well‑executed digital strategy can drive both top‑line growth and margin improvement in the consumer staples sector, setting a strong foundation for continued expansion across Europe.
